Login to Your Account



Clinic Roundup


Monday, July 2, 2012

• Medivir AB of Stockholm, Sweden said that in July it will be initiating a Phase II combination study with TMC435 and daclatasvir (Bristol-Myers Squibb, BMS-790052).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription